Henry Kaminski Henry Kaminski
Meta Amalia Neumann Professorship in Neurology
Professor of Neurology and Rehabilitation Medicine
Professor of Pharmacology and Physiology (Secondary)

Office Phone: 202-741-2710
Email: Email
Department: Neurology and Rehabilitation Medicine


Henry J. Kaminski, MD serves as the Meta A. Neumann Professor of Neurology at the George Washington University. Dr. Kaminski has performed clinical, translational, and basic investigations related to myasthenia gravis for over 25 years. His investigations have defined complement mechanisms in the pathophysiology of myasthenia gravis which led to localize complement inhibition to the neuromuscular junction as a treatment (U.S. Patent No. 8,961,981) and now is working to develop therapeutics based on inhibition of anti-apoptotic protein survivin. He was part of the executive committee of MGTX, the NIH-funded study, which demonstrated the efficacy of thymectomy for patients with generalized myasthenia gravis. Has recent work has turned towards objective quantitation of the neuromuscular exam using artificial intelligence. In 2019, Dr. Kaminski established as principal investigator the NIH Rare Disease Clinical Research Network site dedicated to myasthenia gravis, MGNet.


Benatar M, Cutter G, Kaminski HJ. The best and the worst times in therapy development for myasthenia gravis. Muscle Nerve 2023;67:12-16.

Regnault A, Morel T, de la Loge C, Mazerolle F, Kaminski HJ, Habib A. Measuring overall severity of myasthenia gravis (MG): Evidence for the added value of the MG symptoms patient-reported outcome measures. Neurol Ther 2023May 11. doi: 10.1007/s40120-023-00464-x..

Howard JF, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Smilowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI on behalf of the RAISE investigators. Efficacy and safety of zilucoplan in patients with generalised myasthenia gravis: a randomised, double-blind, placebo-controlled, Phase 3 study. Lancet Neurol 2023;22:395-406.

Bril V, Druzdz A, Grosskreutz J, Habib AA, Mantegazza R, Saccon Si, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ, on behalf of the MG0003 study investigators. Efficacy and safety of rozanolixizumab in patients with generalized myasthenia gravis. A randomized, double-blind, placebo-controlled Phase 3 study. Lancet Neurol 2023;22:383-94.

Hamedani AG, McPherson TO, Aban I, Lee I, Kupersmith MJ, Wolfe GI, Kaminski HJ. Attitudes and beliefs toward thymectomy in the myasthenia gravis patient registry. J Clin Neuromusc Disease 2023;24:222-228.

Garbey M, Lesport Q, Joerger Q, Girma H, McKnett S, Abu-Rub M, Kaminski HJ. A digital telehealth system to compute the myasthenia gravis core examination metrics. JMIR Neurotechnology 2023;2:e43387.

Guptill JT, Benatar M, Granit V, Habib AA, Howard, Jr. JF, Barnett-Tapia C, Nowak RJ, Ikjae L, Ruzhansky K, Dimachkie MM, Cutter G, Kaminski HJ, on behalf of MGNet Clinical Trial Outcome Measure Working Group. Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials. Neurology 2023 Apr 19;doi: 10.1212/WNL.0000000000207278.

Sikorski P, Li Y, Cheema M, Wolfe G, Kusner LL, Aban I, Kaminski HJ. Serum lipidomic and metabolomic predictors of treatment response in patients with myasthenia gravis. PLOS One 2023 (in press)

Prado IV, Shymansky J, Kaminski, HJ, Apte A, Mortman K, Barak S. A rare case of metaplastic thymoma presenting with myasthenia gravis. Am J Surg Path 2023 Apr 24;10668969231168344. doi: 10.1177/10668969231168344

Lesport Q, Joerger Q, Kaminski HJ, Girma H, McKnett S, Abu-Rub M, Garbey M. Eye segmentation method for telehealth: Application to myasthenia gravis examination. Sensors (in press).

Verschuuren J, Palace J, Murai H, Tannemaat M, Kaminski H, Bril V. Advances and ongoing research in treatment of autoimmune neuromuscular transmission diseases. Lancet Neurol 2022:21:189-202.

Green JD, Macek M, International Myasthenia Gravis Genomics Consortium, Drachman DB, Traynor BJ. Analyses of a cohort of myasthenia gravis patients reveals new evidence for genetic contributions to the disease. PNAS 2022;119 e2108672119.

Gutierrez G, Girma H, Kuhnell P, Macaluso M, Kaminski HJ. Impact of the Covid-19 epidemic on a US sample of patients with myasthenia gravis. Therap Adv Rare Dis 2022; 3:1-8.

Kaminski HJ, Denk J. Corticosteroid resistance in myasthenia gravis. Front Neurology 2022 Apr 25;13:886625. doi: 10.3389/fneur.2022.886625.

Industry Relationships and Collaborations

This faculty member (or a member of their immediate family) has reported a financial interest with the health care related companies listed below. These relations have been reported to the University and, when appropriate, management plans are in place to address potential conflicts.

  • ARC Biotechnology, LLC